𝔖 Bobbio Scriptorium

✦ LIBER ✦

Safety and efficacy of an extended course of alefacept of up to 12 additional weekly doses following a standard 12-week course of alefacept

Book ID: 116583985
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 48 KB
Volume: 58
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2007.10.585

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A comparison of the safety and efficacy

A comparison of the safety and efficacy of alefacept 30 mg IM weekly for 12 weeks with alefacept 30 mg IM weekly for 6 weeks followed by alefacept 15 mg IM weekly for 6 weeks in patients with chronic plaque psoriasis

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 46 KB

A 12-week open-label followed by 4-week

A 12-week open-label followed by 4-week double-blind study to determine the safety and efficacy of an extended course of alefacept (LFA-3/igg1 fusion protein) in subjects with chronic plaque psoriasis

✍ Carin H. Gribetz; Robin Blum; Steven Cohen; Mark Lebwohl 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 57 KB

P.246 The efficacy of a 12 weeks course

P.246 The efficacy of a 12 weeks course of pegylated interferon alpha-2b (Peg-IFN) and ribavirin (RBV) is similar to a standard 24 weeks course, regardless of basal viremic level

✍ R. Bonardi; A. Manca; M. Tabone; A. Mattalia; M. Rizzetto 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 143 KB

An open-label single-center study to ass

An open-label single-center study to assess the safety and efficacy of dose escalation of alefacept 15 mg IM for 6 weeks followed by 6 weeks of 30 mg IM in patients with moderate to severe chronic plaque psoriasis

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 52 KB

OC-27 An open, randomized, multicentre t

OC-27 An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-interferon α-2b versus a 12 week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with acute hepatitis C

✍ Santantonio, T.; Fasano, M.; Sagnelli, E.; Tundo, P.; Babudieri, S.; Fabris, P.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Efficacy and tolerability of varenicline

Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers

✍ Masakazu Nakamura; Akira Oshima; Yoko Fujimoto; Nami Maruyama; Taro Ishibashi; K 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 244 KB